Finger-prick dried blood spots supported monitoring of both adalimumab and anti-adalimumab antibodies in inflammatory rheumatic disease: biologic TDM without a venous draw.
In AML and CLL, 91% of VAMS venetoclax results fell within 20% of plasma after individualised haematocrit correction; in home sampling, 18 of 21 patients self-sampled independently and 76% of returned samples were analysable, which shows home microsampling is workable, though the authors ask for multicentre validation.
Home DBS sampling gave testosterone results that agreed well with venous blood in men on intramuscular testosterone undecanoate, but showed falsely high values in those using topical gel, likely from skin contamination. Patients preferred home collection for its convenience, suggesting DBS is viable for decentralised monitoring of injectable testosterone if patients are taught proper technique.
Capillary dried blood spot concentrations of levetiracetam agreed closely with plasma, with 92.1% within 20% of the mean and no proportional bias, and capillary matched venous dried blood spot with acceptable deviations; samples remained stable during postal transit, enabling at‑home self‑sampling for therapeutic drug monitoring.
The study found that dried blood spot sampling showed good agreement with plasma concentrations for vancomycin and creatinine, with most differences within 20%, and patients preferred the finger prick method over venepuncture, supporting its use for decentralised therapeutic drug monitoring.